You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapsing forms of MS

Showing 1 - 25 of 7,122
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Sclerosis Trial in Los Angeles (Blood draw for future biomarker analysis)

Completed
Has Results
  • Multiple Sclerosis
  • Blood draw for future biomarker analysis
  • Los Angeles, California
    Investigational Site Number 8400001
Mar 15, 2022

Diroximel Fumarate Real-world Experience in Canada and Israel

Recruiting
  • Relapsing Forms of MS
  • Diroximel Fumarate
  • Haifa, Israel
  • +5 more
Jan 31, 2023

Multiple Sclerosis Trial in Newark (Betaseron, Copaxone)

Completed
Has Results
  • Multiple Sclerosis
  • Newark, New Jersey
    New Jersey Medical School
Oct 18, 2021

Multiple Sclerosis (MS) Trial in Dallas (Alemtuzumab)

Completed
Has Results
  • Multiple Sclerosis (MS)
  • Dallas, Texas
  • +1 more
Jan 24, 2022

Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis Trial

Active, not recruiting
  • Secondary Progressive Multiple Sclerosis
  • +2 more
  • Minneapolis, Minnesota
  • +2 more
Mar 29, 2022

Relapsing Multiple Sclerosis Trial in Boston (Ofatumumab, [F-18]PBR06)

Recruiting
  • Relapsing Multiple Sclerosis
  • Boston, Massachusetts
    Partners MS Center, 60 Fenwood Road
Jul 20, 2021

Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting Trial in Germany, United States (Tetanus, diphtheria, and acellular

Recruiting
  • Multiple Sclerosis
  • Multiple Sclerosis, Relapsing-Remitting
  • Tetanus, diphtheria, and acellular pertussis vaccine
  • +2 more
  • Palo Alto, California
  • +47 more
Jun 24, 2022

Study of Diroximel Fumarate in the Real-World Setting

Recruiting
  • Relapsing Forms of MS
  • Diroximel Fumarate
  • Washington, District of Columbia
  • +11 more
May 9, 2022

Multiple Sclerosis, Relapsing-Remitting Trial in Canada, United States (23-PPV, 13-PCV Booster, Influenza Vaccine)

Completed
Has Results
  • Multiple Sclerosis, Relapsing-Remitting
  • 23-PPV
  • +5 more
  • Cullman, Alabama
  • +21 more
Apr 4, 2022

Multiple Sclerosis Trial in Aurora (Ocrelizumab, Rituximab)

Completed
Has Results
  • Multiple Sclerosis
  • Aurora, Colorado
    University of Colorado Hospital
Jul 1, 2021

Multiple Sclerosis Trial (Frexalimab, Teriflunomide, Placebo infusion)

Not yet recruiting
  • Multiple Sclerosis
  • (no location specified)
Nov 15, 2023

Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto

Not yet recruiting
  • Multiple Sclerosis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Palo Alto, California
    Stanford Multiple Sclerosis Center
Nov 13, 2023

Relapsing Forms of Multiple Sclerosis Trial (BIIB091, DRF, Placebo)

Not yet recruiting
  • Relapsing Forms of Multiple Sclerosis
  • (no location specified)
Mar 23, 2023

Multiple Sclerosis Trial (Dimethyl fumarate)

Not yet recruiting
  • Multiple Sclerosis
  • Dimethyl fumarate
  • (no location specified)
Dec 12, 2022

Ocrelizumab and Ofatumumab Administration in Relapsing Multiple

Completed
  • Relapsing Forms of Multiple Sclerosis
  • Lutherville, Maryland
  • +1 more
Oct 19, 2022

Relapsing Forms of Multiple Sclerosis Trial in Australia, United States (EHP-101 25 mg OD, EHP-101 25 mg BID, EHP-101 50 mg OD)

Recruiting
  • Relapsing Forms of Multiple Sclerosis
  • EHP-101 25 mg OD
  • +3 more
  • Cullman, Alabama
  • +3 more
Apr 29, 2022

Integrated Digital Solutions in Medical Care of Multiple

Not yet recruiting
  • Relapsing Remitting Multiple Sclerosis
  • MS Care Platform (icobrain ms and icompanion ms)
  • (no location specified)
Jul 10, 2023

Multiple Sclerosis Trial in Stockholm (temelimab 18 mg/kg, temelimab 36 mg/kg, temelimab 54 mg/kg)

Completed
  • Multiple Sclerosis
  • temelimab 18 mg/kg
  • +3 more
  • Stockholm, Sweden
    Center for Neurology, Academic Specialist Center
Jul 4, 2022

Relapsing Remitting Multiple Sclerosis Trial in Portland (3 mg Melatonin, 5 mg Melatonin)

Active, not recruiting
  • Relapsing Remitting Multiple Sclerosis
  • 3 mg Melatonin
  • 5 mg Melatonin
  • Portland, Oregon
    Providence MS Center
May 5, 2022

Multiple Sclerosis (MS) Trial in Canada, United States (elezanumab, )

Completed
  • Multiple Sclerosis (MS)
  • Birmingham, Alabama
  • +48 more
Dec 1, 2021

Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Demyelinating Autoimmune Diseases, CNS Trial in Amsterdam

Recruiting
  • Multiple Sclerosis
  • +5 more
  • Amsterdam, Netherlands
    Amsterdam UMC, location VUmc
Apr 17, 2023

Mechanistic Studies of Teriflunomide in RRMS

Active, not recruiting
  • Relapsing Remitting Multiple Sclerosis
  • Ann Arbor, Michigan
    University of Michigan
Jul 27, 2022

Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI

Recruiting
  • Multiple Sclerosis, Relapsing-Remitting
  • West Orange, New Jersey
    Kessler Foundation
Oct 12, 2022

Multiple Sclerosis Trial in Amsterdam (MS Sherpa)

Recruiting
  • Multiple Sclerosis
  • MS Sherpa
  • Amsterdam, Netherlands
    Amsterdam UMC, locatie VUmc
Nov 4, 2023

Multiple Sclerosis (MS) Patients

Not yet recruiting
  • Multiple Sclerosis, Relapsing-Remitting
  • +2 more
    • (no location specified)
    Dec 15, 2022